Summary
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.
Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of $4.3 billion by 2025.
Highlights
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.
- What will be the effect of recent and upcoming changes in national immunization schedules?
- How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?
- What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?
- Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?
Key Findings
- GlobalData has calculated that the global seasonal influenza vaccine market generated about $3.1 billion in sales in 2015. This global market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 3.3%, reaching sales of $4.3 billion by 2025. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based, quadrivalent vaccines. Further growth is anticipated due to the launch of cell-culture. quadrivalent vaccines in the 7MM. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of $1 billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching $2.6 billion by 2025, while Japan will experience marginal growth, with a CAGR of 0.3%.
- KOLs interviewed by GlobalData repeatedly identified the effectiveness of seasonal influenza vaccines as the number one unmet need. They argued that the influenza virus rapid antigenic drift coupled to a time-consuming egg-based vaccine manufacturing approach are barriers to increasing vaccine efficacy and duration.
- GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.
Scope
- Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.
- Top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned
Sanofi
CSL Limited (Seqirus)
GlaxoSmithKline
AstraZeneca (MedImmune)
Protein Sciences Corporation
Mitsubishi Tanabe Pharma
Novavax
Mylan
Daiichi Sankyo
'
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 24
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 33
3.1.3 Symptoms and Prognosis 34
4 Epidemiology 36
4.1 Disease Background 36
4.2 Risk Factors and Comorbidities 38
4.3 Global Trends 38
4.3.1 Historical Perspective of Vaccination Coverage 39
4.3.2 Laboratory Confirmed Influenza Cases 42
4.3.3 Hospitalization Due to Influenza 42
4.3.4 Influenza Averted Cases 43
4.4 Forecast Methodology 43
4.4.1 Sources Used Tables 44
4.4.2 Forecast Assumptions and Methods 48
4.4.3 Sources Not Used 62
4.5 Epidemiological Forecast for Seasonal Influenza (2015-2025) 63
4.5.1 Seasonal Influenza Vaccination 63
4.5.2 Seasonal Influenza Vaccination Rates 69
4.5.3 Diagnosed Outpatient Influenza-Like Illness Incident Cases 72
4.5.4 Lab Confirmed Incident Cases of Seasonal Influenza 79
4.5.5 Influenza-Related Hospitalized Incident Cases 85
4.5.6 Cases Averted by Seasonal Influenza Vaccinations 91
4.6 Discussion 95
4.6.1 Epidemiological Forecast Insight 95
4.6.2 Limitations of Analysis 96
4.6.3 Strengths of Analysis 97
5 Disease Management 98
5.1 Seasonal Influenza Immunization Policy 98
5.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 99
5.2 US 101
5.2.1 Influenza Immunization Recommendations and Policies 102
5.2.2 Clinical Practice 105
5.3 France 107
5.3.1 Influenza Immunization Recommendations and Policies 108
5.3.2 Clinical Practice 110
5.4 Germany 111
5.4.1 Influenza Immunization Recommendations and Policies 113
5.4.2 Clinical Practice 115
5.5 Italy 117
5.5.1 Influenza Immunization Recommendations and Policies 119
5.5.2 Clinical Practice 121
5.6 Spain 123
5.6.1 Influenza Immunization Recommendations and Policies 124
5.6.2 Clinical Practice 126
5.7 UK 127
5.7.1 Influenza Immunization Recommendations and Policies 129
5.7.2 Clinical Practice 131
5.8 Japan 133
5.8.1 Influenza Immunization Recommendations and Policies 134
5.8.2 Clinical Practice 135
6 Competitive Assessment 138
6.1 Overview 138
6.2 Product Profiles - Major Brands, Inactivated Vaccines 140
6.2.1 Fluzone Quadrivalent 140
6.2.2 Fluzone High-Dose 146
6.2.3 Fluzone Intradermal 153
6.2.4 Vaxigrip 161
6.2.5 Fluarix Tetra 167
6.2.6 Fluvirin 174
6.2.7 Afluria 179
6.2.8 Agrippal 185
6.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 189
6.3.1 Fluad 189
6.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 196
6.4.1 FluMist Quadrivalent 196
6.5 Product Profiles - Major Brands, Cell Cultured Vaccines 204
6.5.1 Flublok 204
6.5.2 Flucelvax 211
6.6 Other Seasonal Influenza Vaccines 218
6.6.1 Influvac 218
6.6.2 Minor Brands 220
7 Unmet Needs and Opportunity Analysis 221
7.1 Overview 221
7.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 225
7.2.1 Unmet Need 225
7.2.2 Gap Analysis 226
7.2.3 Opportunity 229
7.3 Immunization Policies Targeting Children and Adolescents 230
7.3.1 Unmet Need 230
7.3.2 Gap Analysis 231
7.3.3 Opportunity 231
7.4 Enhanced Vaccine Efficacy in High-Risk Groups 233
7.4.1 Unmet Need 233
7.4.2 Gap Analysis 234
7.4.3 Opportunity 236
7.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 237
7.5.1 Unmet Need 237
7.5.2 Gap Analysis 238
7.5.3 Opportunity 239
7.6 Improving the Cost-Effectiveness of Influenza Vaccines 240
7.6.1 Unmet Need 240
7.6.2 Gap Analysis 241
7.6.3 Opportunity 242
7.7 Vaccines with Broader Influenza Strain Coverage 243
7.7.1 Unmet Need 243
7.7.2 Gap Analysis 244
7.7.3 Opportunity 245
7.8 Improved Vaccine Safety Profile 246
7.8.1 Unmet Need 246
7.8.2 Gap Analysis 247
7.8.3 Opportunity 248
8 Pipeline Assessment 249
8.1 Overview 249
8.2 Promising Vaccines in Clinical Development 250
8.2.1 Seasonal Influenza VLP Vaccine 255
8.2.2 VN-100 264
8.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 272
8.3 Promising Vaccines in Early-Stage Development 280
8.3.1 FLU-v 281
8.3.2 M-001 282
8.3.3 TAK-850 283
8.3.4 VAX-2012Q 283
8.4 Other Vaccines in Development Outside the 7MM 284
9 Current and Future Players 285
9.1 Overview 285
9.2 Trends in Corporate Strategy 289
9.3 Company Profiles - Major Players 292
9.3.1 Sanofi 292
9.3.2 CSL Limited (Seqirus) 294
9.3.3 GlaxoSmithKline 296
9.3.4 AstraZeneca (MedImmune) 297
9.3.5 Protein Sciences Corporation 300
9.3.6 Mitsubishi Tanabe Pharma 302
9.3.7 Novavax 303
9.4 Other Companies 305
9.4.1 Mylan 305
9.4.2 Daiichi Sankyo 306
10 Market Outlook 307
10.1 Global Markets 307
10.1.1 Forecast 307
10.1.2 Drivers and Barriers - Global Issues 313
10.2 US 314
10.2.1 Forecast 314
10.2.2 Key Events 321
10.2.3 Drivers and Barriers 322
10.3 France 323
10.3.1 Forecast 323
10.3.2 Key Events 327
10.3.3 Drivers and Barriers 327
10.4 Germany 328
10.4.1 Forecast 328
10.4.2 Key Events 332
10.4.3 Drivers and Barriers 332
10.5 Italy 333
10.5.1 Forecast 333
10.5.2 Key Events 337
10.5.3 Drivers and Barriers 338
10.6 Spain 339
10.6.1 Forecast 339
10.6.2 Key Events 343
10.6.3 Drivers and Barriers 343
10.7 United Kingdom 344
10.7.1 Forecast 344
10.7.2 Key Events 348
10.7.3 Drivers and Barriers 349
10.8 Japan 349
10.8.1 Forecast 349
10.8.2 Key Events 354
10.8.3 Drivers and Barriers 355
11 Appendix 356
11.1 Bibliography 356
11.2 Abbreviations 394
11.3 Methodology 398
11.4 Forecasting Methodology 398
11.4.1 Vaccine Coverage 398
11.4.2 Vaccines Included 399
11.4.3 Key Launch Dates 399
11.4.4 Influenza Vaccine Tender System Assumptions 400
11.4.5 General Pricing Assumptions 401
11.4.6 Individual Vaccine Assumptions 402
11.4.7 Pricing of Pipeline Agents 410
11.5 Primary Research - KOLs Interviewed for this Report 411
11.6 Primary Research - Prescriber Survey 414
11.7 About the Authors 415
11.7.1 Analyst 415
11.7.2 Therapy Area Director 415
11.7.3 Epidemiologists 416
11.7.4 Director of Epidemiology 417
11.7.5 Global Director of Therapy Analysis and Epidemiology 417
11.8 About GlobalData 418
11.9 Disclaimer 418
1.1 List of Tables
Table 1: Notable Influenza Pandemics 33
Table 2: Influenza Symptoms 35
Table 3: Risk Factors and Comorbidities for Seasonal Influenza 38
Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage 41
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza 44
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI 45
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza 46
Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases 47
Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza 48
Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza 62
Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015-2025 64
Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015 65
Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015 67
Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015-2025 69
Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71
Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 73
Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015 75
Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015 77
Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 80
Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015 82
Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015 84
Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 86
Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015 88
Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015 90
Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 92
Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015 94
Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 99
Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 101
Table 29: Country Profile - US 102
Table 30: Country Profile - France 108
Table 31: Country Profile - Germany 113
Table 32: Country Profile - Italy 118
Table 33: Country Profile - Spain 124
Table 34: Country Profile - UK 129
Table 35: Country Profile -Japan 134
Table 36: Leading Seasonal Influenza Vaccines, 2016 139
Table 37: Product Profile - Fluzone Quadrivalent 141
Table 38: Immunogenicity Profile of Fluzone Quadrivalent 142
Table 39: Local and Systemic AEs of Fluzone Quadrivalent 143
Table 40: Fluzone Quadrivalent SWOT Analysis, 2016 144
Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 146
Table 42: Product Profile - Fluzone High-Dose 147
Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone 149
Table 44: Local and Systemic AEs of Fluzone High-Dose 150
Table 45: Fluzone High-Dose SWOT Analysis, 2016 151
Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 153
Table 47: Product Profile - Fluzone Intradermal 155
Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 157
Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 158
Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 159
Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 161
Table 52: Product Profile - Vaxigrip 163
Table 53: Cumulative Incidence of Influenza Infection in Children 164
Table 54: Local and Systemic AEs of Vaxigrip 165
Table 55: Vaxigrip SWOT Analysis, 2016 165
Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 167
Table 57: Product Profile - Fluarix Tetra 169
Table 58: Immunogenicity Profile of Fluarix Tetra 170
Table 59: Local and Systemic AEs of Fluarix Tetra 171
Table 60: Fluarix Tetra SWOT Analysis, 2016 172
Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 174
Table 62: Product Profile - Fluvirin 175
Table 63: Immunogenicity of Fluvirin in Adults 176
Table 64: Local and Systemic AEs of Fluvirin 177
Table 65: Fluvirin SWOT Analysis, 2016 178
Table 66: Global Sales Forecast ($m) for Fluvirin, 2015-2025 179
Table 67: Product Profile - Afluria 180
Table 68: Immunogenicity of Afluria in Adults 181
Table 69: Local and Systemic AEs of Afluria 182
Table 70: Afluria SWOT Analysis, 2016 183
Table 71: Global Sales Forecast ($m) for Afluria, 2015-2025 184
Table 72: Product Profile - Agrippal 186
Table 73: Immunogenicity of Agrippal 187
Table 74: Local and Systemic AEs of Agrippal 187
Table 75: Agrippal SWOT Analysis, 2016 188
Table 76: Global Sales Forecast ($m) for Agrippal, 2015-2025 189
Table 77: Product Profile - Fluad 191
Table 78: Immunogenicity Comparison of Fluad Versus Agriflu 192
Table 79: Local and Systemic AEs of Fluad 193
Table 80: Fluad SWOT Analysis, 2016 194
Table 81: Global Sales Forecast ($m) for Fluad, 2015-2025 196
Table 82: Product Profile - FluMist Quadrivalent 198
Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 200
Table 84: AEs of FluMist Quadrivalent 201
Table 85: FluMist Quadrivalent SWOT Analysis, 2016 201
Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 203
Table 87: Product Profile - Flublok 205
Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 207
Table 89: Local and Systemic AEs of Flublok 208
Table 90: Flublok SWOT Analysis, 2016 209
Table 91: Global Sales Forecast ($m) for Flublok, 2015-2025 211
Table 92: Product Profile - Flucelvax 213
Table 93: Immunogenicity of Flucelvax 214
Table 94: Local and Systemic AEs of Flucelvax 215
Table 95:Flucelvax SWOT Analysis, 2016 216
Table 96: Global Sales Forecast ($m) for Flucelvax, 2015-2025 218
Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 220
Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 224
Table 99: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 251
Table 100: Quadrivalent Versions of Marketed Vaccines 254
Table 101: Product Profile - Seasonal Influenza VLP Vaccine 257
Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 262
Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 264
Table 104: Product Profile - VN-100 266
Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 267
Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 268
Table 107: VN-100 SWOT Analysis, 2016 271
Table 108: Global Sales Forecast ($m) for VN-100, 2015-2025 272
Table 109: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 274
Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 278
Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 280
Table 112: Promising Vaccines in Early-Stage Development, 2016 281
Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 284
Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016 288
Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 293
Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 295
Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 297
Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 299
Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 301
Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 303
Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 305
Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015-2025 310
Table 123: Seasonal Influenza Vaccines Market - Drivers and Barriers, 7MM, 2015-2025 313
Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025 319
Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015‒2025 321
Table 126: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 322
Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025 325
Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015‒2025 327
Table 129: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 327
Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025 330
Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015‒2025 332
Table 132: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 332
Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025 335
Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015‒2025 337
Table 135: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 338
Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025 341
Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015‒2025 343
Table 138: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 343
Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025 346
Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015‒2025 348
Table 141: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 349
Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025 352
Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015‒2025 354
Table 144: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 355
Table 145: Key Launch Dates 400
Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 414
1.2 List of Figures
Figure 1: Influenza Virus Structure 30
Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015-2025 64
Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015 66
Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015 68
Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015-2025 70
Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71
Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 74
Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015 76
Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015 78
Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015 79
Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 81
Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015 83
Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015 85
Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 87
Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015 89
Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015 91
Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 93
Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015 95
Figure 19: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 251
Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 252
Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015-2025 289
Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025 312
Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025 320
Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025 326
Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025 331
Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025 336
Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025 342
Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025 347
Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025 353
